NASDAQ: KROS
Keros Therapeutics Inc Earnings Dates, Reports, Calls

Keros Therapeutics earnings were -$85.1M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest KROS earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$23.7M, up 1.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, KROS reported annual earnings of $87.0M, with -146.4% growth.

KROS earnings history

Current Revenue
$33.2M
Current Earnings
-$85.1M
Current Profit Margin
-256.6%

KROS Return on Equity

Current Company
-17%
Current Industry
-142.5%
Current Market
14%
KROS's Return on Equity (-17%)... subscribe to Premium to read more.
High Return on Equity Performance

KROS Return on Assets

Current Company
-15.8%
Current Industry
-13%
KROS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when KROS announces earnings.

KROS Return on Capital Employed

Current Company
-30.16%
Current Industry
-9.2%
KROS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

KROS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
KROS-$86.28M-$85.15MN/A-$2.53
VYGR-$107.62M-$116.64MN/A-$1.98
RNAN/AN/AN/AN/A
TNXP-$145.40M-$147.39MN/A-$14.53
CNTX-$40.10M-$40.23MN/A-$0.42

Keros Therapeutics Earnings Reports & History FAQ

What were Keros Therapeutics's earnings last quarter?

On KROS's earnings call on Invalid Date, Keros Therapeutics (NASDAQ: KROS) reported Q1 2026 earnings per share (EPS) of -$1.21, up 133.06% year over year. Total KROS earnings for the quarter were -$23.71 million. In the same quarter last year, Keros Therapeutics's earnings per share (EPS) was $3.66.

If you're new to stock investing, here's how to buy Keros Therapeutics stock.

Is Keros Therapeutics profitable or losing money?

As of the last Keros Therapeutics earnings report, Keros Therapeutics is currently losing money. Keros Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$85.15 million, a 2,121.49% decrease year over year.

What was KROS's earnings growth in the past year?

As of Keros Therapeutics's earnings date in Invalid Date, Keros Therapeutics's earnings has grown year over year. KROS earnings in the past year totalled -$85.15 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.